JP2013505236A - Ｈｉｖ−１抗体 - Google Patents

Ｈｉｖ−１抗体 Download PDF

Info

Publication number
JP2013505236A
JP2013505236A JP2012529742A JP2012529742A JP2013505236A JP 2013505236 A JP2013505236 A JP 2013505236A JP 2012529742 A JP2012529742 A JP 2012529742A JP 2012529742 A JP2012529742 A JP 2012529742A JP 2013505236 A JP2013505236 A JP 2013505236A
Authority
JP
Japan
Prior art keywords
antibody
hiv
cells
antibodies
cll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012529742A
Other languages
English (en)
Japanese (ja)
Inventor
ヘイネス，バートン・エフ
トーマラス，ジョージア
シェン，ショーンナ
ディミトロフ，ディミター・エス
チュー，ジョンユー
ウォン，クァン−キ
チオラッジ，ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2013505236A publication Critical patent/JP2013505236A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012529742A 2009-09-16 2010-09-16 Ｈｉｖ−１抗体 Ceased JP2013505236A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27234909P 2009-09-16 2009-09-16
US61/272,349 2009-09-16
US24879609P 2009-10-05 2009-10-05
US61/248,796 2009-10-05
PCT/US2010/002515 WO2011034582A2 (fr) 2009-09-16 2010-09-16 Anticorps anti-vih-1

Publications (1)

Publication Number Publication Date
JP2013505236A true JP2013505236A (ja) 2013-02-14

Family

ID=43759219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529742A Ceased JP2013505236A (ja) 2009-09-16 2010-09-16 Ｈｉｖ−１抗体

Country Status (5)

Country Link
EP (1) EP2477658A2 (fr)
JP (1) JP2013505236A (fr)
AU (1) AU2010296058A1 (fr)
CA (1) CA2774446A1 (fr)
WO (1) WO2011034582A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271022A4 (fr) * 2015-03-19 2018-10-31 Duke University Anticorps neutralisant le vih-1 et leurs utilisations
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
BR112019013468A8 (pt) 2016-12-27 2022-11-22 Univ Rockefeller Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3259040A1 (fr) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
WO2024097957A1 (fr) * 2022-11-03 2024-05-10 Duke University Nouveaux anticorps contre le vih et leurs procédés de fabrication et d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1868651A4 (fr) * 2005-04-12 2010-10-06 Univ Duke Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine

Also Published As

Publication number Publication date
CA2774446A1 (fr) 2011-03-24
WO2011034582A3 (fr) 2011-09-15
WO2011034582A2 (fr) 2011-03-24
AU2010296058A1 (en) 2012-05-03
EP2477658A2 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
EP1450857B1 (fr) Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
JP2013505236A (ja) Ｈｉｖ−１抗体
US20120269821A1 (en) Hiv-1 antibodies
CA2809837A1 (fr) Anticorps neutralisants anti-virus de l'immunodeficience humaine (vih)
JPWO1994020632A1 (ja) 抗ｈｉｖモノクローナル抗体
Kumar et al. A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
US20070292390A1 (en) Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
CN110483636B (zh) 人源抗HIVgp120特异性抗体Z166及其应用方法
CN103224559B (zh) 人源hiv广谱中和抗体a16及其相关生物材料与应用
EP2190875B1 (fr) Anticorps catalytiques contre le VIH gp120
CN102190726B (zh) 一种人源HIV抗体的Fab片段及其编码基因与应用
US20150004190A1 (en) Vaccine compositions for hiv prevention and treatment
JP2010509340A (ja) バイナリエピトープ抗体およびｂ細胞スーパー抗原免疫刺激物質
CN107383190B (zh) 人源抗HIV gp41特异性抗体及其应用
CN101222937A (zh) 具有不抗il-2而抗hiv中和活性的抗体或其片段
CN101198374B (zh) 具有抗hiv中和活性的抗体或其片段
EP4174083A1 (fr) Neutralisation des anticorps monoclonaux contre les sarbecovirus
CN121335920A (zh) 靶向HIV Env上的CD4结合位点的广谱中和抗体
CN122003433A (zh) 靶向hiv env上的v3聚糖位点的广谱中和抗体
JP2888981B2 (ja) Ｈｉｖ免疫療法
TW202519546A (zh) 靶向hiv套膜上之v3醣位點之廣效性中和抗體
RU2134724C1 (ru) Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
Gaudet The Isolation of gp41 Specific Monoclonal Antibodies from the Cervical IgA Repertoire of Highly Exposed Persistently Seronegative (HEPS) Commercial Sex Workers from Nairobi, Kenya using Mammalian Cell Display
US20160347828A1 (en) Non-HIV Vaccine Antigen from the Vaginal Microbiota Capable of Inducing a Mucosal Neutralizing Protective Antibody Response Against HIV Infection
CN102731650A (zh) 一种抑制病毒感染人体t淋巴细胞的单克隆抗体

Legal Events

Date Code Title Description
A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A043

Effective date: 20130607